Retatrutide Delivers up to 30% Weight Loss in Phase 3 Trials
Retatrutide just delivered some very impressive phase3 results for $LLY at 4mg, 9mg and 12mg -- https://t.co/7sKbaDoInq Retatrutide is their GLP-3 ie triple agonist which hits the GLP, GIP and Glucagon receptors. At the primary endpoint of 80 weeks... patients on 4mg, 9mg and 12mg doses lost an average 19.0%, 25.9% and 28.3% respectively. At the extended endpoint of 104 weeks... patients on 4mg, 9mg and 12mg doses lost an average of 27.9%, 29.5% and 30.3% respectively. At the primary endpoint of 80 weeks... 52.9% of patients on 9mg lost more than 25% of their bodyweight 62.5% of patients on 12mg lost more than 25% of their bodyweight 37.9% of patients on 9mg lost more than 30% of their bodyweight 45.3% of patients on 12mg lost more than 30% of their bodyweight 20.8% of patients on 9mg lost more than 35% of their bodyweight 27.2% of patients on 12mg lost more than 35% of their bodyweight I'm still curious to know how Retatrutide stacks up against Semaglutide ($NVO) and Tirzepatide ($LLY) in terms of muscle loss / muscle preservation because this is the metric that could really separate them from the other two and turn Retatrutide into the biggest selling drug of all time. NFA. DYOR. *We have a position in $LLY at @FirstWaveFund
Analysts Underestimated Nvidia Revenue by over Six‑fold.
This graph/chart for $NVDA is just hilarious... it shows where the sell side analysts were 3 years ago on their forward estimates... this was around the time that $NVDA started to crush numbers from the H100. Back in May 2023, analysts...
RDDT Appears Massively Undervalued Despite Strong Earnings Outlook
$RDDT down -4.7% today, continues to trade like crap. When $RDDT reports Q2 earnings... revenues should be up at least +50% YoY... and EPS should be up at least +60% YoY $RDDT market cap right now is $28B... when they report...
TMDX Poised for Massive Organ Transport Growth by 2032
I spent some quality time today with the $TMDX team at their HQ in Andover, MA. I’ll share some deeper thoughts over the next few days including my bear case, base case, bull case and super bull case for the...
NU Shifts to AI‑Native Model, Targets Growth Over Margins
$NU -- great note out of Goldman Sachs analyst after meeting with $NU management (post earnings) I can't share the whole report but I'll share this part... $NU indicated that it is already seeing material impacts from Al adoption across customer...
Spreadsheet Reveals Undervalued Cybersecurity Stocks Like APP, RDDT
I put together a spreadsheet of 60+ software, cloud and cybersecurity companies: - % down from their 52 week high - % up from their 52 week low - current NTM ev/revs multiple - current NTM ev/ebitda multiple - 2 year expected revenue growth...
FPS Posts Explosive Growth, Becomes Top Fund Pick
Very strong earnings report this morning by $FPS (Forgent Power Solutions)... we increased our position today... now a top 15 position at @FirstWaveFund Here is the press release: https://t.co/vNSIoTbsZx FY2026 Q3 results: Revenues of $379M, up 103% YoY Bookings of $867M, up 308% YoY Backlog...
AppLovin Generates $8.4M Revenue per Employee
I've seen several accounts post the chart below showing revenue per employee at the big tech companies... I think it's worth mentioning @AppLovin -- $APP is expected to do $8.3B revenues in 2026 $APP did $1.842B revenues in Q1 which means their...
MELI at 2022 Lows, 49% Revenue Surge Fuels Upside
Big spot for $MELI today... testing the VWAP from the 2022 lows... down -40% from the highs... trading at it's lowest ebitda multiple since the 2008/2009 GFC lows... company is seeing some margin compression because their credit portfolio is growing...
Short‑Term Pain, Long‑Term Gain: TMDX Still Bullish
Just wrapped up a 45 minute call with $TMDX management… lots of good stuff.. obviously there’s some short term pain from margin compression due to bigger investments (R&D, trials, international expansion, etc) but my conviction has not changed and I...
AAOI Down 15% Before Triple‑Digit Growth Surge
Nice recap of the $AAOI earnings report… it was lovely to see the stock down -15% last night when the real growth ramp doesn’t kick in for 1-2 quarters at which point $AAOI will likely be growing triple digits YoY...
IREN Surges 150%, Eyes $100 with 5GW Power
Congrats to the $IREN shareholders... big day for all of us... we've been patient... and patience paid off... nice to see the investment thesis play out with some help today from $NVDA and their $2B investment... https://t.co/1pRKNoJUAZ $IREN is up...
APP Appears 50% Undervalued with Explosive Growth
I think $APP does at least 56% revenue growth in 2026 and at least 42% revenue growth in 2027... which gets them to $12B+ revenues in 2027... assuming 84% ebitda margins... $APP now trading at less than 16x 2027 ev/ebitda...
APP's AXON Launch Set to Drive 2026‑28 Growth
$APP just announced their new AXON platform will be GA ie "general availability" starting in June... this will be a big catalyst for growth in the second half of 2026 and throughout 2027 and 2028.
Staying the Course: TMDX’s Long‑Term Thesis Remains Intact
Excellent post (below) on $TMDX, I'll do another detailed post in the next few days however in the meantime I'm doing calls with sell-side analysts and management. Here's what I'll say for now... Today is obviously frustrating for long-term shareholders but I...